Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Cancer J
Main Authors: Nazha, Aziz, Sekeres, Mikkael A., Komrokji, Rami, Steensma, David P., Kantarjian, Hagop, Roboz, Gail, Fenaux, Pierre, Prebet, Thomas, Azarnia, Nozar, Zbyszewski, Patrick S., Fruchtman, Steven M., Santini, Valeria, Silverman, Lewis R., Platzbecker, Uwe, Garcia-Manero, Guillermo
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2017
Assuntos:
Correspondence
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5802598/
https://ncbi.nlm.nih.gov/pubmed/29238044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-017-0018-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados